1 (previously presented). A compound of the formula I



I

wherein

R1, R2 are each independently H, F, Cl, Br, $(C_1\text{-}C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1\text{-}C_6)$-alkyl, $COO(C_1\text{-}C_6)$-alkyl, COOH, $CO\text{-}(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-COOH, $(C_0\text{-}C_6)$-alkyl $\text{-}COO(C_1\text{-}C_6)$-alkyl or $SO_2\text{-}(C_1\text{-}C_6)$-alkyl;

R3 is OH, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl or O-$(C_2\text{-}C_6)$-alkynyl, wherein said $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl and O-$(C_2\text{-}C_6)$-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-$(C_1\text{-}C_6)$-alkyl, NH_2, $NH(C_1\text{-}C_6)$-alkyl or $N((C_1\text{-}C_6)\text{-alkyl})_2$;

A is N;

B, D and E are CH;

m is 2;

or a pharmaceutically acceptable salt thereof.

2 (canceled).

3 (currently amended). The compound of Claim [[2]] 1 wherein:

R1 is H or F;

R2 is **[[**each independently**]]** H, F, Cl, Br, (C_1-C_6)-alkyl, CF_3, OCF_3, O-(C_1-C_6)-alkyl, $COO(C_1$-C_6)-alkyl, COOH, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkyl-COOH, (C_0-C_6)-alkyl-$COO(C_1$-C_6)-alkyl or SO_2-(C_1-C_6)-alkyl;

R3 is OH, (C_1-C_6)-alkyl, (C_0-C_6)-alkyl-aryl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or O-(C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, (C_0-C_6)-alkyl-aryl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and O-(C_2-C_6)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-(C_1-C_6)-alkyl, NH_2, $NH(C_1$-C_6)-alkyl or $N((C_1$-C_6)-alkyl$)_2$;

A is N;

B, D, E are each CH;

m is 2;

or a pharmaceutically acceptable salt thereof.

4 (previously presented). The compound of Claim 3 wherein:

R1 is H or F;

R2 is H, Cl, (C_1-C_6)-alkyl, CF_3, $COO(C_1$-C_6)-alkyl or COOH,

R3 is H or phenyl;

X is OH, O-(C_1-C_6)-alkyl, NH_2, $NH(C_1$-C_6)-alkyl or $N((C_1$-C_6)-alkyl$)_2$;

A is N;

B, D, E are each CH;

m is 2;

or a pharmaceutically acceptable salt thereof.

5 (original). A pharmaceutical composition comprising one or more compounds of Claim 1 and a pharmaceutically acceptable carrier.

6 (canceled).

7 (canceled).

8 (withdrawn). A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

9 (withdrawn). A method of treating type II diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10 (withdrawn). A method of treating treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

11 (withdrawn). A method of treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12 (withdrawn). A method of treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13 (withdrawn). A process of preparing a compound of Claim 1, which comprises reacting ureas of the formula 2 with reactive acid derivatives of formula 4 selected from the group comprising acid chlorides and anhydrides:



2



4

wherein R1, R2, R3, A, B, D and E are as defined in claim 1 and Y is selected from the group comprising Cl or



wherein R1 is as defined above.

14 (withdrawn). A process of preparing a compound of Claim 1, which comprises reacting an aniline derivative of the formula 3 with an aroyl isocyanate of the formula 4



3



4

wherein R1, R2, R3, A, B, D and E are each as defined in Claim 1 and Y is NCO.